195 related articles for article (PubMed ID: 35684529)
1. Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management.
Belal A; Elanany MA; Santali EY; Al-Karmalawy AA; Aboelez MO; Amin AH; Abdellattif MH; Mehany ABM; Elkady H
Molecules; 2022 Jun; 27(11):. PubMed ID: 35684529
[TBL] [Abstract][Full Text] [Related]
2. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Laghezza A; Tortorella P; Agamennone M
ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
[TBL] [Abstract][Full Text] [Related]
3. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
Kalva S; Vinod D; Saleena LM
J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
Kalva S; Agrawal N; Skelton AA; Saleena LM
Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
[TBL] [Abstract][Full Text] [Related]
5. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
[TBL] [Abstract][Full Text] [Related]
6. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights in repurposing selective COX-2 inhibitor celecoxib against matrix metalloproteinases in potentiating delayed wound healing: a molecular docking and MMPB/SA based analysis of molecular dynamic simulations.
Mude L; Jupudi S; Swaroop AK; Tallapaneni V; Karri VVSR
J Biomol Struct Dyn; 2024 Mar; 42(5):2437-2448. PubMed ID: 37160705
[TBL] [Abstract][Full Text] [Related]
8. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
9. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study.
Marcial BL; Sousa SF; Barbosa IL; Dos Santos HF; Ramos MJ
J Phys Chem B; 2012 Nov; 116(46):13644-54. PubMed ID: 23121406
[TBL] [Abstract][Full Text] [Related]
10. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
11. An integrated structure- and pharmacophore-based MMP-12 virtual screening.
Ramezani M; Shamsara J
Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648
[TBL] [Abstract][Full Text] [Related]
12. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Natural Product Inhibitors against Matrix Metalloproteinase 9 Using Quantum Mechanical Fragment Molecular Orbital-Based Virtual Screening Methods.
Lim H; Hong H; Hwang S; Kim SJ; Seo SY; No KT
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457257
[TBL] [Abstract][Full Text] [Related]
14. Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking.
Wang Y; Yang L; Hou J; Zou Q; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Feb; 37(3):649-670. PubMed ID: 29380672
[TBL] [Abstract][Full Text] [Related]
15. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
Singh T; Adekoya OA; Jayaram B
Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
[TBL] [Abstract][Full Text] [Related]
16. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products.
Gao Q; Wang Y; Hou J; Yao Q; Zhang J
J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
18. Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.
Ammazzalorso A; De Filippis B; Campestre C; Laghezza A; Marrone A; Amoroso R; Tortorella P; Agamennone M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782083
[TBL] [Abstract][Full Text] [Related]
19. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring.
Shamsara J
Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516
[TBL] [Abstract][Full Text] [Related]
20. An integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitors.
Di Pizio A; Agamennone M; Aschi M
PLoS One; 2012; 7(11):e47774. PubMed ID: 23144829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
